Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 915 of 1433 results for primary care

  1. Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    5 July 2023
    View recommendations

    Sections for TA908

  2. Etelcalcetide for treating secondary hyperparathyroidism (TA448)

    Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA448

  3. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

    Technology appraisal guidance
    Published
    2 October 2019
    View recommendations

    Sections for TA604

  4. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA462

  5. Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

    Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

    Technology appraisal guidance
    Published
    6 February 2018
    View recommendations

    Sections for TA504

  6. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing a pulmonary embolism (PE) or another deep vein thrombosis in adults.

    Technology appraisal guidance
    Published
    25 July 2012
    View recommendations

    Sections for TA261

  7. Synergo for non-muscle-invasive bladder cancer (HTG601)

    Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.

    HealthTech guidance
    Published
    30 November 2021
    View recommendations

    Sections for HTG601

  8. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MIB174)

    NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .

    Medtech innovation briefing
    Published
    4 March 2019

  9. Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)

    NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .

    Medtech innovation briefing
    Published
    30 August 2022

  10. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.

    Technology appraisal guidance
    Published
    3 October 2018
    View recommendations

    Sections for TA543

  11. Patient attitudes and beliefs about peripheral arterial disease:- What is the effect of people's attitudes and beliefs about their peripheral arterial disease on the management and outcome of their condition?

    the majority of people diagnosed with peripheral arterial disease in a primary care setting. Research is required to further investigate...

    Research recommendation
    Published
    9 June 2015

  12. Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

    Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.

    Technology appraisal guidance
    Published
    11 September 2024
    View recommendations

    Sections for TA1002

  13. Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)

    NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .

    Medtech innovation briefing
    Published
    14 December 2018

  14. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England

  15. URO17 for detecting bladder cancer (MIB250)

    NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .

    Medtech innovation briefing
    Published
    4 February 2021